abmart-banner
Global R&D Pipeline
My Favorite
Hot Targets:
Home>AbMart>

Global R&D Pipeline

c-Kit
Back
Total number of drugs
184
Phase II and later clinical stages
20.1%
Involving companies
229
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
DrugDrug Name EnDrug TypeTreatment FieldMechanism of ActionOriginatorDeveloperIndicationHighest Development StageHighest Development Stage (China)Approved Countries/RegionsApproved TimeApproved Time (China)Special ReviewADC TypeADC LinkerADC PayloadADC DARDrug NameAntibody TypeADC Linking SiteOperation
BezuclastinibBezuclastinibSmall molecule drugNeoplasms Digestive System Disorders Skin and Musculoskeletal Diseases Other Diseases Immune System Diseases Hemic and Lymphatic DiseasesStem cell growth factor receptor inhibitorsPlexxikon, Inc.Cogent Biosciences, Inc.NDA/BLAUnited StatesBezuclastinib
detail  >
Nilotinib HydrochlorideNilotinib HydrochlorideSmall molecule drugNeoplasms Hemic and Lymphatic Diseases Nervous System Diseases Digestive System Disorders Skin and Musculoskeletal Diseases Other Diseases Immune System Diseases Endocrinology and Metabolic DiseaseColony stimulating factor 1 receptor antagonists Discoidin domain receptor 1 antagonists Stem cell growth factor receptor inhibitorsNovartis Pharma AGNovartis Pharmaceuticals Corp.Accord Healthcare SLNovartis AGNovartis Europharm Ltd.Azurity Pharmaceuticals, Inc.Totalclarity, Inc.Xspray Pharma ABNovartis Pharma Schweiz AGNovartis Pharmaceuticals (HK) Ltd.Georgetown UniversityNovartis Pharma KKNovartis Pharmaceuticals Australia Pty Ltd.ApprovedApprovedUnited States China European Union Japan United Kingdom Australia Switzerland Iceland Liechtenstein Norway2007-07-242009-07-14United StatesNilotinib Hydrochloride
detail  >
DashatinibDashatinibSmall molecule drugNeoplasms Immune System Diseases Hemic and Lymphatic Diseases Skin and Musculoskeletal Diseases Nervous System Diseases Cardiovascular Diseases Congenital Disorders Digestive System Disorders Other DiseasesEphrin type-A receptor 2 antagonists Tyrosine-protein kinase FYN inhibitors Tyrosine-protein kinase LCK inhibitors Platelet-derived growth factor receptor beta inhibitors Tyrosine-protein kinase SRC inhibitors Yes tyrosine protein kinase inhibitors Stem cell growth factor receptor inhibitorsBristol Myers Squibb Co.Accord Healthcare SLBristol Myers Squibb Co.Bristol-Myers Squibb Pharma EEIGGeorgetown UniversityXspray Pharma ABThe Naval Medical University of PLAHanda Pharmaceuticals, Inc.Wayne State University FoundationGSK PlcAstex Pharmaceuticals, Inc.UCL School of PharmacyProDigest BVUniversity of Pittsburgh School of MedicineYale School of MedicineApprovedApprovedUnited States China European Union Japan Australia Iceland Liechtenstein Norway2006-06-282011-09-07United StatesDashatinib
detail  >
Sunitinib MalateSunitinib MalateSmall molecule drugNeoplasms Digestive System Disorders Endocrinology and Metabolic Disease Skin and Musculoskeletal Diseases Urogenital Diseases Other Diseases Eye DiseasesColony stimulating factor 1 receptor antagonists Tyrosine-protein kinase receptor FLT3 inhibitors Platelet-derived growth factor receptor alpha inhibitors Platelet-derived growth factor receptor beta inhibitors Tyrosine-protein kinase receptor RET inhibitors Vascular endothelial growth factor receptor 1 antagonists Vascular endothelial growth factor receptor 2 antagonists Vascular endothelial growth factor receptor 3 antagonists Stem cell growth factor receptor inhibitorsPfizer Inc.Pfizer Japan, Inc.C.P. Pharmaceuticals International CVPfizer Australia Pty Ltd.Pfizer Ltd.Accord Healthcare SLPfizer Inc.Pfizer Italia SrlApprovedApprovedUnited States China European Union Japan United Kingdom Australia Iceland Liechtenstein Norway2006-01-262007-10-30United StatesSunitinib Malate
detail  >
Sorafenib TosylateSorafenib TosylateSmall molecule drugNeoplasms Digestive System Disorders Endocrinology and Metabolic Disease Urogenital Diseases Other Diseases Respiratory Diseases Congenital DisordersSerine/threonine-protein kinase B-raf inhibitors C-Raf kinase inhibitors Tyrosine-protein kinase receptor FLT3 inhibitors Platelet-derived growth factor receptor beta inhibitors Tyrosine-protein kinase receptor RET inhibitors Vascular endothelial growth factor receptor 1 antagonists Vascular endothelial growth factor receptor 2 antagonists Vascular endothelial growth factor receptor 3 antagonists Stem cell growth factor receptor inhibitorsOnyx Pharmaceuticals, Inc.Genentech, Inc.Merck Sharp & Dohme Corp.Fudan UniversityBayer Australia Ltd.Bayer AGBayer Healthcare LLCAccord Healthcare SLBayer PlcDisruptive Pharma AB (Sweden)Bayer Yakuhin Ltd.Bayer HealthCare Pharmaceuticals, Inc.Hutchison MediPharma Ltd.Bayer HealthCare AGBayer Schering Pharma AGApprovedApprovedUnited States China European Union Japan United Kingdom Australia Iceland Liechtenstein Norway2005-12-012006-09-12United StatesSorafenib Tosylate
detail  >
Imatinib mesylateImatinib mesylateSmall molecule drugNeoplasms Immune System Diseases Digestive System Disorders Hemic and Lymphatic Diseases Skin and Musculoskeletal Diseases Other Diseases Respiratory Diseases Congenital DisordersBcr-Abl tyrosine kinase inhibitors Platelet-derived growth factor receptor alpha inhibitors Stem cell growth factor receptor inhibitorsNovartis Pharma AGHangzhou Chance Pharmaceuticals Co., Ltd.The Children's Oncology Group Foundation, Inc.Novartis Europharm Ltd.Novartis Pharmaceuticals Corp.Teva Pharmaceuticals Europe BVNovartis Pharmaceuticals Australia Pty Ltd.Accord Healthcare SLNovartis Pharma KKUniversity of California San DiegoNational Cancer InstituteShorla Pharma Ltd.Novartis Pharma Schweiz AGUniversity of Wisconsin-MadisonTenax Therapeutics, Inc.ApprovedApprovedUnited States China European Union Japan Australia Iceland Liechtenstein Norway2001-05-102002-04-01United StatesImatinib mesylate
detail  >
BarzolvolimabBarzolvolimabMonoclonal antibodyImmune System Diseases Skin and Musculoskeletal Diseases Congenital DisordersStem cell growth factor receptor inhibitorsYale UniversityCelldex Therapeutics, Inc.Phase 3Barzolvolimab
detail  >
Famitinib MalateFamitinib MalateSmall molecule drugNeoplasms Urogenital Diseases Respiratory Diseases Skin and Musculoskeletal Diseases Digestive System Disorders Other DiseasesAXL receptor tyrosine kinase inhibitors Fibroblast growth factor receptors antagonists Tyrosine-protein kinase Mer inhibitors Vascular endothelial growth factor receptor 2 antagonists Vascular endothelial growth factor receptor 3 antagonists Stem cell growth factor receptor inhibitorsJiangsu Hengrui Pharmaceuticals Co., Ltd.Fudan UniversityJiangsu Hengrui Pharmaceuticals Co., Ltd.Hengrui (USA) Ltd.ApprovedApprovedChina2025-05-272025-05-27ChinaFamitinib Malate
detail  >
CediranibCediranibSmall molecule drugNeoplasms Nervous System Diseases Digestive System Disorders Endocrinology and Metabolic Disease Urogenital Diseases Other Diseases Respiratory Diseases Skin and Musculoskeletal DiseasesPlatelet-derived growth factor receptor beta inhibitors Vascular endothelial growth factor receptor 1 antagonists Vascular endothelial growth factor receptor 2 antagonists Vascular endothelial growth factor receptor 3 antagonists Stem cell growth factor receptor inhibitorsAstraZeneca PLCAstraZeneca PLCNational Cancer InstituteThe University of Texas MD Anderson Cancer CenterPhase 3Phase 3United StatesCediranib
detail  >
OlverembatinibOlverembatinibSmall molecule drugNeoplasms Hemic and Lymphatic Diseases Immune System Diseases Digestive System Disorders Skin and Musculoskeletal Diseases Other Diseases Urogenital DiseasesBCR-ABL T315I mutation inhibitors Stem cell growth factor receptor inhibitorsGuangzhou Shunjian Biomedical Technology Co. Ltd.Ascentage Pharma Group International Co., Ltd.Ascentage Pharma Group, Inc.Innovent Biologics, Inc.Guangzhou Shunjian Biomedical Technology Co. Ltd.ApprovedApprovedChina Macao2021-11-242021-11-24Breakthrough TherapyOlverembatinib
detail  >
Total 184 data
1
2
3
4
5
6
...
18
19